Market Overview

UPDATE: Piper Jaffray Lifts Synageva PT on Attractive Upcoming LAL-D Treatment

Share:
Related GEVA
Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted
Clear Channel Outdoor, Oasis Petroleum And Other Insiders Have Been Buying

Piper Jaffray published a report Monday that maintained a Neutral rating on Synageva (NASDAQ: GEVA) and raised its price target from $53 to $57.

Piper Jaffray noted, "We continue to believe sebelipase alfa represents an attractive treatment option for LAL-D, with recent 38 week Phase I/II data providing additional confirmation of the drug's long-term clinical utility. Despite our enthusiasm for sebelipase alfa, we remain Neutral on GEVA shares given what we see to be an absence of meaningful newsflow following the commencement of the ARISE Phase III trial in January. While we remain positive on GEVA shares over the longer term, we believe shares will remain range-bound as the trial progresses."

Synageva closed Monday at $54.28.

Latest Ratings for GEVA

DateFirmActionFromTo
Oct 2014SunTrust Robinson HumphreyInitiates Coverage onBuy
Jul 2014CitigroupInitiates Coverage onNeutral
Jul 2014JP MorganMaintainsOverweight

View More Analyst Ratings for GEVA
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (GEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters